Inogen, Inc (INGN) vs MaxCyte, Inc. (MXCT)
Inogen, Inc and MaxCyte, Inc. are both Medical Devices companies. Inogen, Inc is the larger, with a market value of $138.8M against $122.8M — 1.1× the size. Inogen, Inc grew revenue faster over the last twelve months: 3.15% against −13.2%. Inogen, Inc has the higher net margin (−6.94% vs −114.8%) and the higher return on invested capital (−28.4% vs −49.2%). Across the 17 metrics below, Inogen, Inc leads on 12 and MaxCyte, Inc. on 5.
Valuation
Profitability
| Metric | INGN | MXCT | Medical Devices median |
|---|---|---|---|
| Gross margin | 44.51% | 79.23% | 56.01% |
| Operating margin | (8.71%) | (134.59%) | (15.03%) |
| Net margin | (6.94%) | (114.77%) | (20.40%) |
| Free cash flow margin | (2.22%) | (76.14%) | (7.24%) |
| Return on equity | (13.14%) | (20.39%) | (15.32%) |
| Return on assets | (8.23%) | (17.62%) | (19.72%) |
| Return on invested capital | (28.35%) | (49.23%) | (10.33%) |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack